Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484431 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01484431 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 20 participants.
The verdict
NCT01484431, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
Interventions
- DRUG Tadalafil- Tablet or Oral suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-07-17 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484431
The ClinicalTrials.gov registry entry for NCT01484431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tadalafil- Tablet or Oral suspension is the first listed.
NCT01484431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484431 about?
NCT01484431 is a clinical study titled "A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension". The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
What is the current status of trial NCT01484431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-07-17. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT01484431?
The interventions under investigation include: Tadalafil- Tablet or Oral suspension (DRUG).
Who is sponsoring clinical trial NCT01484431?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.